Aeolus Pharmaceuticals Company Description
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States.
The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology.
Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents.
The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson’s disease, as well as AEOL 20415 for treating infectious diseases.
Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
| Country | United States |
| Founded | 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
Contact Details
Address: 26361 Crown Valley Parkway Mission Viejo, Delaware 92691 United States | |
| Phone | 949-481-9825 |
| Website | aeoluspharma.com |
Stock Details
| Ticker Symbol | AOLS |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| ISIN Number | US00765G1094 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Stanley | Vice President of Operations |